Multiple Sclerosis References

Multiple Sclerosis References

[1] Kindred et al. 2017. Cannabis use in people with Parkinson’s disease and Multiple Sclerosis: A Web-based investigationComplimentary Therapies in Medicine 33: 99-104.

[2] Farzaei et al. 2017. Efficacy and tolerability of phytomedicines in multiple sclerosis patients: A reviewCNS Drugs31: 867-889.

[3] Chong et al. 2006. Cannabis use in patients with multiple sclerosisMultiple Sclerosis 12: 646-651.

[4] Rog et al. 2005. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.Neurology 65: 812-819.

[5] Wade et al. 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patientsMultiple Sclerosis 10: 434-441.

[6] Brady et al. 2004. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosisMultiple Sclerosis 10: 425-433.

[7] Vaney et al. 2004. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover studyMultiple Sclerosis 10: 417-424.

[8] Zajicek et al. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis: multicentre randomized placebo-controlled trialThe Lancet 362: 1517-1526.

[9] Page et al. 2003. Cannabis use as described by people with multiple sclerosis [PDF]Canadian Journal of Neurological Sciences 30: 201-205.

[10] Wade et al. 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptomsClinical Rehabilitation 17: 21-29.

[11] Consroe et al. 1997. The perceived effects of smoked cannabis on patients with multiple sclerosisEuropean Journal of Neurology 38: 44-48.

[12] Meinck et al. 1989. Effects of cannabinoids on spasticity and ataxia in multiple sclerosisJournal of Neurology236: 120-122.

[13] Ungerleider et al. 1987. Delta-9-THC in the treatment of spasticity associated with multiple sclerosisAdvances in Alcohol and Substance Abuse 7: 39-50.

[14] Denis Petro. 1980. Marijuana as a therapeutic agent for muscle spasm or spasticityPsychosomatics 21: 81-85.

[15] Jody Corey-Bloom. 2010. Short-term effects of cannabis therapy on spasticity in multiple sclerosis. In: University of San Diego Health Sciences, Center for Medicinal Cannabis Research. Report to the Legislature and Governor of the State of California presenting findings pursuant to SB847 which created the CMCR and provided state funding.

[16] Corey-Bloom et al. 2012. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trialCMAJ 10: 1143-1150.

[17] Clark et al. 2004. Patterns of cannabis use among patients with multiple sclerosisNeurology 62: 2098-2010.

[18] Rudroff and Honce. 2017. Cannabis and multiple sclerosis: The way forwardFrontiers in Neurology 8: 299.

[19] Banwell et al. 2016. Attitudes to cannabis and patterns of use among Canadians with multiple sclerosisMultiple Sclerosis and Related Disorders 10: 123-126.

[20] Reuters News Wire. August 19, 2002. “Marijuana helps MS patients alleviate pain, spasms.”

[21] Pryce et al. 2003. Cannabinoids inhibit neurodegeneration in models of multiple sclerosisBrain 126: 2191-2202.

[22] de Lago et al. 2012. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB(1) receptor-mediated anti-inflammatory effectsNeuropharmacology 62: 2299-2308.

[23] Giacoppo et al. 2015. Purified cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosisEuropean Review for Medical and Pharmacological Sciences 19: 4906-4919.

[24] Killestein et al. 2003. Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis.Journal of Neuroimmunology 137: 140-143.

[25] Kuhlen et al. 2016. Effective treatment of spasticity using dronabinol in pediatric palliative careEuropean Journal of Pediatric Neurology 20: 898-903.

[26] Pryce et al. 2015. Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids. Journal of Neuroimmune Pharmacology 10: 281-292.

[27] Wade et al. 2006. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms of multiple sclerosisMultiple Sclerosis 12: 639-645.

[28] Rog et al. 2007. Oromucosal delta-9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trialClinical Therapeutics 29: 2068-2079.

[29] M. Trojano. 2016. THC:CBD observational study data: Evolution of resistant MS spasticity and associated symptomsEuropean Neurology 75: 4-8.

[30] Secca et al. 2016. The use of medical-grade cannabis in patients non-responders to nabiximolsJourn